BIMG-13. A NOVEL RADIOPHARMACEUTICAL ([18F]DASA-23) TO MONITOR PYRUVATE KINASE M2 INDUCED GLYCOLYTIC REPROGRAMMING IN GLIOBLASTOMA. (25th March 2021)

• Record Type: Journal Article
• Authors: Beinat, Corinne; Patel, Chirag; Haywood, Tom; Murty, Surya; Naya, Lewis; Hayden-Gephart, Melanie; Khalighi, Mehdi; Massoud, Tarik; Iagaru, Andrei; Davidzon, Guido; Thomas, Reena; Nagpal, Seema; Recht, Lawrence; Gambhir, Sanjiv
• Is Part Of: Neuro-oncology advances. Volume 3(2021)Supplement 1
• Page Start: i3
• Page End: i4
• Publication Date: 2021-03-25
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdab024.012
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: BACKGROUND: Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain, making it an important biomarker of cancer glycolytic re-programming. We describe the bench-to-bedside development, validation, and translation of a novel positron emission tomography (PET) tracer to study PKM2 in GBM. Specifically, we evaluated 1-((2-fluoro-6-[ 18 F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([ 18 F]DASA-23) in cell culture, mouse models of GBM, healthy human volunteers, and GBM patients. METHODS: [ 18 F]DASA-23 was synthesized with a molar activity of 100.47 ± 29.58 GBq/µmol and radiochemical purity >95%. We performed initial testing of [ 18 F]DASA-23 in GBM cell culture and human GBM xenografts implanted orthotopically into mice. Next we produced [ 18 F]DASA-23 under current Good Manufacturing Practices United States Food and Drug Administration (FDA) oversight, and evaluated it in healthy volunteers and a pilot cohort of patients with gliomas. RESULTS: In mouse imaging studies, [ 18 F]DASA-23 clearly delineated the U87 GBM from the surrounding healthy brain tissue and had a tumor-to-brain ratio (TBR) of 3.6 ± 0.5. In human volunteers, [ 18 F]DASA-23 crossed the intact blood-brain barrier and was rapidly cleared. In GBM patients, [ 18 F]DASA-23 successfully outlined tumors visible on contrast-enhanced magnetic resonance imaging (MRI). The uptake of [ 18 F]DASA-23 was markedly elevated in GBMs compared to normal brain, and it was able to identify a metabolic non-responder within 1-week of treatment initiation. CONCLUSION: We developed and translated [ 18 F]DASA-23 as a promising new tracer that demonstrated the visualization of aberrantly expressed PKM2 for the first time in human subjects. These encouraging results warrant further clinical evaluation of [ 18 F]DASA-23 to assess its utility for imaging therapy-induced normalization of aberrant cancer metabolism.